PHS
RVNC

PFM Health Sciences’s Revance Therapeutics, Inc. RVNC Stock Holding History

PFM Health Sciences’s Portfolio RVNC Stock Details RVNC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q4 		– Sell
-388,467
Closed -$7.51M – 100
2014
Q3 		$7.51M Buy
388,467
+152,605
+65% +$3.98M 0.17% 56
2014
Q2 		$8.02M Sell
235,862
-85,041
-27% -$2.66M 0.16% 60
2014
Q1 		$10.1M Buy
+320,903
New +$10M 0.18% 61

Other funds holding RVNC

EWM
Essex Woodlands Management The Woodlands, Texas $251M AUM 13.72% 1-Year Est. Return
NHG
NQ HCIF GP Raleigh, North Carolina $50.2M AUM 45.53% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
PC
Polar Capital London, United Kingdom $13.5B AUM 55.9% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
VAM
Visium Asset Management New York $1.43B AUM 3.58% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

PFM Health Sciences's RVNC Position: Q4 2014 in Review

PFM Health Sciences sold out of Revance Therapeutics, Inc. (RVNC) in Q4 2014, closing a stake of 388,467 shares — an estimated $7.51M sold.

PFM Health Sciences first reported a position in RVNC in Q1 2014 and held it in 3 quarters. The position peaked at $10.1M in Q1 2014. 69 funds tracked by Wall St. Rank hold RVNC as of Q4 2014.

  • PFM Health Sciences reported no remaining Revance Therapeutics, Inc. position as of Q4 2014 after selling out during the quarter.
  • PFM Health Sciences sold 388,467 Revance Therapeutics, Inc. shares in Q4 2014, an estimated $7.51M.
  • PFM Health Sciences first reported a position in Revance Therapeutics, Inc. in Q1 2014 and held it in 3 quarters.
  • PFM Health Sciences's Revance Therapeutics, Inc. position peaked at $10.1M in Q1 2014.
  • 69 funds tracked by Wall St. Rank held Revance Therapeutics, Inc. as of Q4 2014.

Based on PFM Health Sciences's 13F filing for Q4 2014, filed 17 Feb 2015.